Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older, weighing at least 35 kg, who have no antiretroviral treatment history, or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Stribild.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• CAB-LA for HIV-1 Prevention: CAB-LA demonstrated superior efficacy in preventing HIV-1 infection with an HIV-1 infection rate of 0.33% compared to 1.46% in the tenofovir disoproxil fumarate-emtricitabine group (RR 0.21, 95% CI 0.07-0.61).
• CAB-LA+RPV-LA for HIV-1 Treatment: Virological suppression rates were 91.43% at 48 and 96 weeks, comparable to 92.2% with daily oral drugs (RR 0.99, 95% CI 0.97-1.02); long-term suppression after 5 years was 80.9%.
• E/C/F/TAF in HIV/HBV-Coinfected Patients: E/C/F/TAF maintained HIV RNA <50 copies/mL in 95.6% at week 24 and 94.2% at week 48, and HBV DNA <20 IU/mL in 92.7% at week 24 and 89.8% at week 48.
• CAB-LA and RPV-LA: Higher incidence of drug-related adverse events compared to placebo (81.6% vs. 6.2%, RR 12.50, 95% CI 3.98-39.23; I²=85%), with common mild or moderate injection site reactions that decreased over time.
• E/C/F/TAF: Significant improvements in renal function and bone mineral density, but an increase in lipid levels was observed. Withdrawal due to adverse effects occurred in 2.6% of patients.
• There is no population types or subgroup information available in the reviewed studies.